Table 2.
Clinical and Serological Profile at 12 Months
| IBCDT n = 30 | MMF n = 20 | CYC n = 10 | P | |
|---|---|---|---|---|
| sCr | 0.89 (0.6–1.4) | 0.85 (0.6–1.4) | 0.97 (0.6–1.7) | 0.68 |
| ESR, median (IQR) | 10.2 (7–27) | 14(8–28) | 21 (8–30) | 0.71 |
| Proteinuria g/24 h, median (IQR) | 0.46 (0.37–0.50) | 0.71 (0.30–0.91) | 0.51 (0.33–0.82) | 0.78 |
| C3/C4 mg/dl, median (IQR) | 97 (79–120)/20 (11–37) | 95 (81–120)/21 (13–40) | 99 (80–120)/20 (10–40) | 0.74 |
| SLEDAI median, (range) | 4 (1–5) | 6 (2–8) | 4 (2–8) | 0.57 |
| Complete renal response, n (%) | 28 (93) | 13 (65) | 7 (70) | 0.03 |
| Partial renal response, n (%) | 2 (7) | 4 (20) | 3 (30) | 0.15 |
| No renal response, n (%) | 0 (0) | 3 (15) | 0 (0) | 0.37 |
| Any renal response, n (%) | 30 (100) | 17 (85) | 10 (100) | 0.32 |
| Time to complete renal response, median months (IQR) | 9 (6–11) | 8 (6–11) | 7(6–11) | 0.87 |
CYC, cyclophosphamide; ESR, erythrocyte sedimentation rate; IBCDT, intensified B-cell depletion induction therapy; IQR, interquartile range; MMF, mycophenolate mofetil; sCR, serum creatinine; SLEDAI, Systemic Lupus Erythematosus Activity Index